EyePoint Pharmaceuticals Inc. (EYPT)
EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. ( EYPT ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants George Elston - Executive VP & CFO Jay Duker - President, CEO & Director Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good morning. My name is Antoine, and I will be your conference operator today.
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.54 per share a year ago.
EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School Conference Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Citi's Biopharma Back to School Conference September 2, 2025 2:30 PM EDT Company Participants Jay Duker - President, CEO & Director George Elston - Executive VP & CFO Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst [Audio Gap] With EyePoint. [Operator Instructions] and welcome as well to those listening on the webcast.
EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants George O. Elston - Executive VP & CFO Jay S.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $0.58 per share a year ago.
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
EyePoint Pharmaceuticals, Inc.'s Duravyu shows promising Phase 2 results in DME, supporting a slightly risky 'Buy' call ahead of pivotal Phase 3 readouts in 2026. Duravyu's potential for less frequent dosing could offer a key advantage over current market leaders Eylea and Vabysmo. Rapid enrollment in Phase 3 trials and robust safety/efficacy data boost confidence, but competition and market fragmentation remain significant risks.
Breakout Momentum Plays You May Not Know About
High volatility has plagued markets throughout much of 2025. While many consider this a bad thing, particularly when trends point downward, it can also create opportunities for momentum investors to capture gains when target stocks are up.
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker - President & Chief Executive Officer Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Jennifer Kim - Cantor Tessa Romero - JPMorgan Tyler Van Buren - TD Cowen Yatin Suneja - Guggenheim Kambiz Yazdi - Jefferies Nick Quartapella - Baird Deb Chatterjee - Jones Yale Jen - Laidlaw & Company Yigal Nochomovitz - Citigroup Operator Good morning. My name is Towanda and I will be your conference operator today.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for EyePoint Pharmaceuticals (EYPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Yigal Nochomovitz - Citigroup Yatin Suneja - Guggenheim Kambiz Yazdi - Jefferies Jennifer Kim - Cantor Fitzgerald Graig Suvannavejh - Mizuho Securities Colleen Kusy - Baird Debanjana Chatterjee - JonesTrading Gregory Harrison - Scotiabank Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good morning.
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for EyePoint Pharmaceuticals (EYPT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
